Personal Profile
Till has a PhD on biosensors from research at University of Stuttgart and the University of Tokyo and a German Habilitation in Analytical Biotechnology. He is an expert in point of care detection of infectious diseases and antimicrobial resistance, conducting research at the interface of biomarkers and rapid diagnostics including for COVID-19. Till is the coordinator of the UK-India project ‘DOSA - Diagnostics for One Health and User Driven Solutions for AMR’, and the JPIAMR-VRI Network AMR Dx Global, succeeding the JPIAMR Transnational Working Group on Rapid Diagnostic Tests. Till has extensive teaching leadership experience as is currently University of Edinburgh Director of Postgraduate Programmes at the Zhejiang University – University of Edinburgh Institute in China, as well as Programme Director of two PhD and one MSc Programme. Till is Editor of the journal JAC-Antimicrobial Resistance and fulfils a range of industrial and institutional advisory roles worldwide. As such he is vice-chair of the Scientific Advisory Board of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), panel member for the Longitude Prize on Antibiotics, Scientific Advisory Board member of CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), of BIRAC (Biotechnology Industry Research Assistance Council) for Devices & Diagnostics under National Biopharma Mission of the Department of Biotechnology of the Indian Government, and the German Institute for Bioprocessing and Analytical Measurement Techniques.
Teaching
- Zhejiang University – University of Edinburgh Dual PhD in Integrative Biomedical Sciences (UoE Programme Director)
- Online MSc Clinical Microbiology and Infectious Diseases (Programme Director, Course organiser)
- ‘Diagnostics and Therapeutics for Infectious Diseases’ Elective in Infectious Disease Honours (Deputy Course Organiser, Lectures)
- ‘Diagnostic Biochips’ in MSc Drug Discovery and Translational Biology (Lectures)
Research
Our research focusses on rapid diagnostics at point of care to enable personalised approaches to medicine. This involves research on novel biosensors, molecular diagnostics, next generation sequencing and biomarkers as well as factors affecting the development and implementation of novel diagnostics. Our main target is the optimisation of antimicrobial therapy to reduce antimicrobial resistance and optimise patient outcome I a wide range of diseases and healthcare settings.
Additional information on AMR: AMR Cross-Council Initiative